Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxVIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial for ADRX-0405 in Advanced Solid Tumors Including Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial for ASP1002, a bispecific antibody
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial: The PHAROS Trial Investigates Novel ACK1 Inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPT217 Receives Second FDA Fast Track Designation for Neuroendocrine Prostate Cancer Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxEmerging Radiopharmaceuticals for Low PSMA-Expressing Prostate Cancer: 67Cu-SAR-bisFAP and 67Cu-SAR-bombesin
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxTags
abiraterone acetate ADT ai in healthcare alphafold AMG 509 androgen deprivation therapy antibody-drug conjugate apalutamide ARANOTE ATM bispecific antibody bone metastases BRCA2 cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology oncolytic virus PARP inhibitor personalized medicine preclinical prostate cancer PSMA radioligand therapy radiopharmaceuticals STEAP1 T-cell therapy theranostics
Latest Posts
- Repurposing Antipsychotic Drugs: Potential New Cancer Treatments January 22, 2025
- We can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues January 21, 2025
- Newsletter 3/2025 January 19, 2025
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025